Raymond James Financial Inc. Has $2.95 Million Stake in CRISPR Therapeutics AG $CRSP

Raymond James Financial Inc. grew its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 5.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,666 shares of the company's stock after purchasing an additional 4,571 shares during the quarter. Raymond James Financial Inc. owned approximately 0.10% of CRISPR Therapeutics worth $2,949,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. ARK Investment Management LLC grew its holdings in CRISPR Therapeutics by 13.3% in the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock worth $345,929,000 after buying an additional 1,192,336 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management acquired a new stake in CRISPR Therapeutics in the first quarter worth approximately $416,000. Cambridge Investment Research Advisors Inc. lifted its position in CRISPR Therapeutics by 14.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company's stock worth $1,334,000 after purchasing an additional 4,914 shares during the period. Green Alpha Advisors LLC lifted its position in CRISPR Therapeutics by 132.9% in the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company's stock worth $1,952,000 after purchasing an additional 32,732 shares during the period. Finally, Vanguard Group Inc. lifted its position in CRISPR Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock worth $60,223,000 after purchasing an additional 33,711 shares during the period. 69.20% of the stock is owned by institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In related news, Director Simeon George purchased 989,812 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the purchase, the director owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. The trade was a 133.69% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.30% of the company's stock.

CRISPR Therapeutics Trading Up 0.7%

NASDAQ:CRSP traded up $0.37 during trading hours on Friday, hitting $56.26. 1,998,586 shares of the stock traded hands, compared to its average volume of 1,761,178. The firm has a 50 day moving average price of $56.73 and a 200 day moving average price of $45.72. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $71.13. The firm has a market cap of $5.12 billion, a price-to-earnings ratio of -10.36 and a beta of 1.81.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. During the same period in the previous year, the business earned ($1.49) EPS. The company's revenue was up 72.5% on a year-over-year basis. Research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CRSP shares. Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Chardan Capital reissued a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Piper Sandler reissued an "overweight" rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Finally, Bank of America dropped their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $71.60.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.